AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Just when investors thought things couldn't get any worse, they do.
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
